An immature inhibin-α-expressing subpopulation of ovarian clear cell carcinoma cells is related to an unfavorable prognosis.
Adenocarcinoma, Clear Cell
/ metabolism
Aldehyde Dehydrogenase
/ metabolism
Cell Line, Tumor
Cell Proliferation
Disease Progression
Drug Resistance, Neoplasm
Female
Gene Silencing
Humans
Inhibins
/ genetics
Ki-67 Antigen
/ metabolism
Middle Aged
Neoplasm Proteins
/ metabolism
Octamer Transcription Factor-3
/ metabolism
Ovarian Neoplasms
/ metabolism
Prognosis
Retrospective Studies
SOXB1 Transcription Factors
/ metabolism
Spheroids, Cellular
/ metabolism
Vascular Endothelial Growth Factor A
/ metabolism
Vascular Endothelial Growth Factor C
/ metabolism
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
31
07
2020
revised:
05
11
2020
accepted:
05
02
2021
pubmed:
22
2
2021
medline:
17
7
2021
entrez:
21
2
2021
Statut:
ppublish
Résumé
Inhibin-α, a member of transforming growth factor-β, is elevated in multiple tumors, but its specific roles are poorly understood. Here, we examined the feature of inhibin-α-expressing cells in ovarian tumors. Immunohistochemically, inhibin-α-expressing tumor cells were detected only in ovarian clear cell carcinoma (OCCC) among various types of ovarian tumors. By comparing the expression of inhibin-α and Ki-67, inhibin-α-expressing tumor cells were revealed to be less proliferative. When spheroids and chemoresistant cells were derived from OCCC cell lines, the expression level of inhibin-α was elevated, and that of an immature marker, aldehyde dehydrogenase, was also elevated. In consistent with this, inhibin-α expression was correlated with other immature markers, such as OCT3/4 and SOX2, and inversely correlated with proliferative marker MKI67 in public database on OCCC. Knockdown of inhibin-α in OCCC cell decreased chemoresistance. Moreover, prognostic analysis with 69 surgically resected OCCC cases revealed that the increased inhibin-α expression was an independent unfavorable prognostic factor. These findings suggested that inhibin-α-expressing subpopulation of OCCC tumor cells appeared to be less proliferative, immature, and angiogenic and to be related to acceleration of malignant progression.
Identifiants
pubmed: 33611864
doi: 10.1002/cam4.3801
pmc: PMC7940216
doi:
Substances chimiques
Ki-67 Antigen
0
MKI67 protein, human
0
Neoplasm Proteins
0
Octamer Transcription Factor-3
0
POU5F1 protein, human
0
SOX2 protein, human
0
SOXB1 Transcription Factors
0
VEGFA protein, human
0
Vascular Endothelial Growth Factor A
0
Vascular Endothelial Growth Factor C
0
inhibin-alpha subunit
0
Inhibins
57285-09-3
Aldehyde Dehydrogenase
EC 1.2.1.3
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1485-1500Informations de copyright
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Gynecol Oncol. 2006 Nov;103(2):559-64
pubmed: 16714056
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8
pubmed: 12629218
J Clin Oncol. 2007 Aug 20;25(24):3621-7
pubmed: 17704411
Cancer. 2000 Jun 1;88(11):2584-9
pubmed: 10861437
J Clin Oncol. 2008 Jan 1;26(1):83-9
pubmed: 18025437
J Cell Biochem. 2011 Oct;112(10):2850-64
pubmed: 21618587
Histopathology. 1999 Sep;35(3):216-20
pubmed: 10469213
Cell Stem Cell. 2007 Sep 13;1(3):313-23
pubmed: 18371365
Gynecol Oncol. 2011 Sep;122(3):541-7
pubmed: 21640372
Nat Cell Biol. 2013 Jul;15(7):807-17
pubmed: 23728425
Gynecol Oncol. 1996 Mar;60(3):412-7
pubmed: 8774649
Cancer Sci. 2008 Apr;99(4):653-8
pubmed: 18377417
Mol Cancer Ther. 2011 Feb;10(2):325-35
pubmed: 21216927
Br J Cancer. 2008 Apr 22;98(8):1389-97
pubmed: 18349830
J Cell Biochem. 2013 Jan;114(1):21-34
pubmed: 22887554
Nat Genet. 2001 Oct;29(2):117-29
pubmed: 11586292
Obstet Gynecol. 1971 Jan;37(1):1-9
pubmed: 4321469
Semin Cancer Biol. 2020 Feb;60:157-165
pubmed: 31491559
J Clin Oncol. 2016 Aug 20;34(24):2881-7
pubmed: 27400948
Oncogene. 2016 Aug 18;35(33):4379-87
pubmed: 26804163
Br J Cancer. 2009 Jun 2;100(11):1784-93
pubmed: 19436293
Genes Cells. 2014 Feb;19(2):141-52
pubmed: 24330390
Biochem Biophys Res Commun. 2013 Nov 1;440(4):731-6
pubmed: 24120944
Oncotarget. 2017 Jan 17;8(3):5603-5618
pubmed: 27901498
Gynecol Oncol. 2008 Feb;108(2):276-81
pubmed: 18063020
Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8
pubmed: 17210912
Cell Stem Cell. 2007 Nov;1(5):555-67
pubmed: 18371393
Histopathology. 1997 Jun;30(6):518-22
pubmed: 9205855
Mol Aspects Med. 2014 Oct;39:110-25
pubmed: 23811037
Cell Transplant. 2002;11(5):451-3
pubmed: 12382672
Dev Biol. 2007 Dec 1;312(1):396-406
pubmed: 17976567
Gynecol Oncol. 1993 Sep;50(3):334-8
pubmed: 8406197
Am J Cancer Res. 2016 Sep 01;6(9):1906-1921
pubmed: 27725898
J Extracell Vesicles. 2017 Aug 8;6(1):1359479
pubmed: 28815003
Clin Cancer Res. 2012 Feb 1;18(3):869-81
pubmed: 22142828
Genes Dev. 2003 May 15;17(10):1253-70
pubmed: 12756227
Cancer Res. 2018 Jun 1;78(11):2978-2989
pubmed: 29535220
Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S161-92
pubmed: 17161157
Cancer Res. 2009 Apr 15;69(8):3382-9
pubmed: 19336570